<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003463</url>
  </required_header>
  <id_info>
    <org_study_id>0901</org_study_id>
    <secondary_id>DUMC-0901-02-5R4</secondary_id>
    <secondary_id>DUMC-0901-02-5R2</secondary_id>
    <secondary_id>DUMC-000901-00-5R2</secondary_id>
    <secondary_id>DUMC-000901-01-5R3</secondary_id>
    <secondary_id>DUMC-0797-99-5RI</secondary_id>
    <secondary_id>DUMC-796-98-5</secondary_id>
    <secondary_id>DUMC-98065</secondary_id>
    <secondary_id>UCLA-9812060</secondary_id>
    <secondary_id>NCI-G98-1464</secondary_id>
    <secondary_id>DUMC-0901-01-5R3</secondary_id>
    <secondary_id>CDR0000066497</secondary_id>
    <nct_id>NCT00003463</nct_id>
  </id_info>
  <brief_title>Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas</brief_title>
  <official_title>Phase I Treatment of Adults With Recurrent Supratentorial High Grade Glioma With Gliadel Wafers Plus Irinotecan (CPT-11)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in&#xD;
      treating patients with recurrent supratentorial high grade gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Define the maximum tolerated dose of irinotecan given in combination with Gliadel wafers&#xD;
           (carmustine) in patients with recurrent glioblastoma multiforme, anaplastic astrocytoma,&#xD;
           or gliosarcoma.&#xD;
&#xD;
        -  Define the toxicity of irinotecan given in combination with Gliadel wafers in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      All patients undergo surgical resection. At the time of surgery, up to eight Gliadel wafers&#xD;
      (containing carmustine) are implanted in the resected tumor cavity.&#xD;
&#xD;
      Cohorts of 3 patients each receive escalating doses of irinotecan IV over 90 minutes once&#xD;
      weekly within 3 weeks after Gliadel wafer implantation. One course of treatment consists of 4&#xD;
      weeks of irinotecan and 2 weeks of rest. If 1 patient experiences dose limiting toxicity&#xD;
      (DLT) at a dose level, an additional 3 patients are entered at that same dose level. If 2&#xD;
      patients experience DLT, the maximum tolerated dose (MTD) has been surpassed and a total of 6&#xD;
      patients are treated at the previous dose level. The MTD is defined as the highest dose in&#xD;
      which no more than 1 of 6 patients experiences DLT.&#xD;
&#xD;
      Treatment continues for up to 12 courses in the absence of unacceptable toxicity and disease&#xD;
      progression.&#xD;
&#xD;
      Patients are followed for at least 4 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18 patients will be accrued into this study over 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">July 2002</completion_date>
  <primary_completion_date type="Actual">July 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polifeprosan 20 with carmustine implant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent supratentorial glioblastoma multiforme, anaplastic&#xD;
             astrocytoma, or gliosarcoma&#xD;
&#xD;
          -  Must be able to undergo surgical resection&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion documented on Gd-MRI within 72 hours&#xD;
             after surgical implantation of Gliadel wafers&#xD;
&#xD;
          -  Not requiring immediate radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 125,000/mm^3&#xD;
&#xD;
          -  Hematocrit at least 29%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT less than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN less than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
        Neurological:&#xD;
&#xD;
          -  Must be neurologically stable&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
               -  No AIDS-related illness&#xD;
&#xD;
          -  No nonmalignant systemic disease that would make patient a poor medical risk&#xD;
&#xD;
          -  No acute infection requiring intravenous antibiotics&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
               -  Negative pregnancy test 24 hours prior to study&#xD;
&#xD;
          -  Effective contraception required of all fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
          -  At least 6 weeks since chemotherapy unless there is unequivocal evidence of tumor&#xD;
             progression after chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 1 week of nonincreasing dose of steroids prior to study&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 6 weeks since radiotherapy unless there is unequivocal evidence of tumor&#xD;
             progression after radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry S. Friedman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 24, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2003</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

